Product information

From Health Canada

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Current status date:

2020-03-05

Original market date: See footnote 1

2020-03-05

Product name:

PMS-FLUTICASONE PROPIONATE/SALMETEROL DPI

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02494515

Product Monograph/Veterinary Labelling:

Date: 2020-11-09 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

PHARMASCIENCE INC
100 6111 Royalmount Ave
Montreal
Quebec
Canada H4P 2T4

Class:

Human

Dosage form(s):

Powder

Route(s) of administration:

Inhalation

Number of active ingredient(s):

2

Schedule(s):

Prescription

 

American Hospital Formulary Service (AHFS): See footnote 3

68:04.00  ,  12:12.08.12 

Anatomical Therapeutic Chemical (ATC): See footnote 4

R03AK06 SALMETEROL AND FLUTICASONE

Active ingredient group (AIG) number:See footnote5

0238341002

List of active ingredient(s)
Active ingredient(s) Strength
FLUTICASONE PROPIONATE 250 MCG / ACT
SALMETEROL (SALMETEROL XINAFOATE) 50 MCG / ACT
Version 4.0.2
Date modified: